Reach for Korlym to fight back withREDUCTIONS IN HbA1c AND T2D MEDICATIONS

Significant 1.1% reduction in HbA1c at Week 241,2,a

Patients experienced a significant 1.1% mean reduction by Week 24/ET (n=25).1

In patients with HbA1c baseline >7%, a significant 1.9% mean reduction was observed by Week 24/ET (n=12).2

Graph showing patients achieving a significant 1.1% mean reduction in HbA1c by Week 24 in the SEISMIC study.

A majority of patients with HbA1c >7% at baseline reached their HbA1c goals.1

  • 75% of patients achieved HbA1c goal <7% (n=9/12)

  • 50% of patients achieved HbA1c goal <6% (n=6/12)

aIn patients with Cushing syndrome and either T2D or impaired glucose tolerance.

Reductions in T2D medications

Some patients were able to reduce their type 2 diabetes medications with Korlym:

Forty-seven percent of patients were able to reduce their T2D medication (n=7/15) in the SEISMIC study.

of patients were able to
reduce their daily T2D
medication (n=7/15)3

Forty-two percent of patients were able to reduce their insulin by at least half (n=5/12) in the SEISMIC study.

of patients were able
to reduce their daily insulin by at
least half (n=5/12)1

References:
  1. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. doi:10.1210/jc.2011-3350
  2. Data on file. DM Cohort 7% line source doc. Corcept Therapeutics, Inc.
  3. Korlym Prescribing Information. Corcept Therapeutics, Inc; 2019.